Clinical Trial Update: Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury [Phase 3]

View source ↗

Summary

Phase 3 trial of reltecimod versus placebo in sepsis-associated acute kidney injury was terminated; results posted in 2021.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury
• Necrotizing Soft Tissue Infection
• Peritonitis

Drugs mentioned

• Reltecimod (Reltecimod)

Snippet

Sponsor: Atox Bio Ltd | Conditions: Acute Kidney Injury, Peritonitis | Phase 3 | Status: TERMINATED | Results posted: 2021-09-16